Our Technology

We have developed a proprietary drug delivery platform designed to precisely deliver biologics to the colon via oral administration. Our technology leverages natural fibers for protective bioencapsulation, ensuring therapeutic proteins remain stable through the upper GI tract and are released directly where they are needed — in the colon.

• Minimizes systemic toxicity

• Enables oral administration of large biologics

• Room-temperature stable, sustainable, green delivery approach

Our Science

Backed by over six years of development at Sorbonne University and building on two decades of research in plant made pharmaceuticals, our platform enables the production and targeted release of a broad range of biologics — from peptides to monoclonal antibodies.

We have generated robust in vivo proof-of-concept data, demonstrating:

• Efficient oral delivery of biologics to the colon

• Preserved activity and target engagement

• Activation of local immune responses

This opens the door to treating diseases such as inflammatory bowel disease, colorectal cancer, GI infections, and others — especially for biologics previously shelved due to systemic toxicity concerns.